Ovarian Cancer Test | GeneType | Genetic Technologies

Don’t let ovarian cancer go unnoticed

Ovarian cancer often doesn’t lead to noticeable symptoms until late in the disease.1

GeneType empowers women by increasing their awareness of the disease.

Colorectal Cancer

Do you know what
you may carry?

Is geneType for Ovarian Cancer right for you?

GeneType for Ovarian Cancer is for:

  • Women
  • Non-Hispanic Whites
  • Aged 40 years or older
  • No known hereditary breast and ovarian cancer (HBOC) gene mutation e.g. BRCA1 or BRCA2 
Multi Test risk reduction plan with Doctor

Simple, actionable results

GeneType reports help you and your health provider translate your personal clinical, family and genetic data into an actionable prevention health plan.

Unlike other tests, your test results are provided in simple language that you can understand.

Sample patient report

Have questions? We have answers.

If your question is not shown here, please contact us directly.

Who is this test not suitable for?

This test is not applicable to women who have a personal history of ovarian cancer or who have already been shown to have an HBOC mutation, for example in the BRCA1 or BRCA2 gene, or a diagnosis of a genetic syndrome that may be associated with elevated risk of ovarian cancer. In this case, your health provider will refer you to a specialist for genetic counselling.

Will insurance cover this test?

GeneType for Ovarian Cancer combines several of risk factor, such as age, family history, and your DNA markers, into one comprehensive risk assessment.

Know your risk of ovarian cancer
so you can take action

Interested in ordering more than one disease? Order geneType Multi-Test.

See individual disease pages for more information about each test.

The Multi-Risk suite of tests is for adults 40-69 years of age. At maximum, a woman would be eligible for 5 diseases in the panel; a man would be eligible for 4. If patient is younger than 40, they may qualify for geneType's breast or colorectal risk assessments only.

Coming soon: melanoma, pancreatic cancer and atrial fibrillation geneType tests. Patient eligibility dependent on personal medical history, age, sex and self-identified race/ethnicity

What’s happening?

References
  1. US Preventive Services Task Force. JAMA 2018;319(6):588–594.
  2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 2.2022 — March 9, 2022.

Accredited For Compliance With NPAAC Standards And ISO 15189

CLIA Number 99D2023356